StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note released on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of Titan Pharmaceuticals stock opened at $3.20 on Friday. Titan Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $14.80. The business’s fifty day moving average price is $3.65 and its 200 day moving average price is $4.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- The 3 Best Retail Stocks to Shop for in August
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- How to Evaluate a Stock Before Buying
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.